#Biotech Drugmaker Actinium Pharmaceuticals Is Creating New Ways To Battle Cancer - @silviecitasblog via @Benzinga $ATNM Read the full article here:
Actinium Pharma
722 posts
Actinium Pharma
@ActiniumPharma
- Register for our next #webinar - "Can Older Rel/Ref #AML Patients with Active Disease be Transplanted?" presented by Dr. Mitchell Sabloff from @OttawaHospital on Aug 5. Sponsored by @ActiniumPharma Registration is FREE for CTTC members: ow.ly/LdVE50AtjdR #HSCT
- We are honored for Iomab-B and the @SIERRATrial to be featured in MedPage Today’s #AML Year in Review. We look forward to presenting additional data from the Phase 3 SIERRA Trial at #ASH20 this weekend. $ATNM Read the full article via @medpagetoday:
- Our 100% remission rate data will be live today at 3:00 PM ET during an oral presentation at #ASH2020. More details about the oral presentation here: ir.actiniumpharma.com/press-releases…
- Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia. Read the full news release here: ir.actiniumpharma.com/press-releases… $ATNM #Tandem23
- We are pleased to share our latest news featured in @AmPharmRev - Actimab-A CLAG-M Trial for Relapsed or Refractory AML Achieves 100% Remission Rate. Read the full article here: americanpharmaceuticalreview.com/1315-News/5702… $ATNM #Pharma #AML #Patients
- Iomab-B was highlighted in today’s CME session “The Convergence of Innovative Therapy and AlloHCT in AML: Applying Current Evidence to Improve Outcomes Across Patient Populations” at #Tandem23. We look forward to full Phase 3 SIERRA results being presented Saturday.
- Our SIERRA Trial is the only randomized Phase 3 trial to offer Bone Marrow Transplant BMT as an option for patients over the age of 55 with active R/R AML. Learn more about our recent data here: ir.actiniumpharma.com/press-releases…
00:00 - At #ASH2020, our 3 oral presentations & 1 poster presentation will demonstrate the clinical progress we have seen not only with Iomab-B, but our other programs including Actimab-A in combination with novel & approved therapeutic agents ir.actiniumpharma.com/press-releases… $ATNM #ASH #Oncology
- We will be featured in 3 oral presentations at ASH, 2 focused on our pivotal Phase 3 SIERRA trial for Iomab-B & 1 on the Actimab-A CLAG-M combination trial, as well as a poster presentation. $ATNM #Oncology #BMT #Hematology Explore our ASH abstracts here: ashpublications.org/blood/issue/13…
- Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 75% of Total Patient Enrollment. Learn about our detailed results presented at #ASH20 here: ir.actiniumpharma.com/press-releases… $ATNM #Oncology #Healthcare #BMT #Hematology #AML
- Actinium Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B. Read the full news release here: ir.actiniumpharma.com/press-releases… $ATNM #AML #BMT
- Actinium Announces Expansion of R&D Team and Facilities to Accelerate Research Programs Focused on Solid Tumors and Novel Combinations with Checkpoint Inhibitors and Radioconjugates Read the full news release here: ir.actiniumpharma.com/press-releases… $ATNM #BloodCancer #RadioTherapy
